Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / September 10, 2021 / Levi & Korsinsky, LLP announces that class actions have been filed on behalf of shareholders of the following publicly traded companies. Shareholders interested in serving as principal plaintiff have until the time limits indicated to apply to court. Further details on the cases can be found at the links provided. There is no cost or obligation for you.
Shareholders live, click here: https://www.zlk.com/pslra-1/live-ventures-incorporated-loss-submission-form?prid=19492&wire=1
ATIP Shareholders, click here: https://www.zlk.com/pslra-1/ati-physical-therapy-inc-fka-fortress-value-acquisition-corp-ii-loss-submission-form?prid=19492&wire=1
SPPI shareholders Click here: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?prid=19492&wire=1
* ADDITIONAL INFORMATION BELOW *
Live Ventures Incorporated (NASDAQ: LIVE)
LIVE Lawsuit on behalf of: investors who bought from December 28, 2016 to August 3, 2021
Lead Applicant Deadline : October 12, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/live-ventures-incorporated-loss-submission-form?prid=19492&wire=1
According to the complaint filed, during the Class Period, Live Ventures Incorporated made materially false and / or misleading statements and / or failed to disclose that: 1) Live’s earnings per share for fiscal 2016 n was actually only $ 6.33 per share; (2) the Company used an artificially low number of shares to increase earnings per share by 40%; (3) Live had overstated pre-tax earnings for fiscal 2016 by 20% by including $ 915,500 of “other income” related to certain changes that were not negotiated until after the end of the fiscal year; (4) The acquisition of ApplianceSmart by Live was not finalized during the first quarter of 2017; (5) the use of December 30, 2017 as the “acquisition date” and the recognition of its income did not comply with generally accepted accounting principles; (6) By falsely stating that the acquisition was completed during the quarter, Live recognized a windfall purchase gain, which allowed the Company to report positive net income in what would otherwise have been a unprofitable quarter; (7) between fiscal 2016 and fiscal 2018, the CEO of Live received approximately 94% more in compensation than was disclosed to investors; and (8) as a result of the foregoing, the Defendants’ positive statements regarding the business, operations and prospects of the Company were substantially misleading and / or lacked reasonable basis.
ATI Physical Therapy, Inc. f / k / a Fortress Value Acquisition Corp. II (NYSE: ATIP)
This lawsuit is on behalf of investors who: (a) bought or otherwise acquired securities of ATI between April 1, 2021 and July 23, 2021 inclusive and / or (b) held class A ordinary shares of FVAC as of May 24, 2021 and were eligible to vote at FVAC’s special meeting on June 15, 2021.
Lead Applicant Deadline : October 15, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ati-physical-therapy-inc-fka-fortress-value-acquisition-corp-ii-loss-submission-form?prid=19492&wire = 1
According to the complaint filed, (1) ATI was experiencing attrition among its physiotherapists; (2) ATI faces increasing competition for clinicians in the workforce; (3) due to the above, the Company had difficulty retaining therapists and incurred increased labor costs; (4) due to the labor shortage, the Company would open fewer new clinics; and (5) as a result of the foregoing, the Defendants’ positive statements regarding the business, operations and prospects of the Company were substantially misleading and / or lacked reasonable basis.
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)
SPPI action on behalf of: investors who bought from December 27, 2018 to August 5, 2021
Lead Applicant Deadline : November 1, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?prid=19492&wire=1
According to the complaint filed, during the Class Period, Spectrum Pharmaceuticals, Inc. made materially false and / or misleading statements and / or failed to disclose that: (i) the ROLONTIS manufacturing facility , an experimental analogue of granulocyte colony stimulating factor, maintained deficient controls and / or procedures; (ii) the aforementioned shortcomings reduced the likelihood that the Food and Drug Administration would approve ROLONTIS (“BLA”) Biologics License Application in its current form; (iii) Spectrum had therefore greatly overestimated the prospects for approval of ROLONTIS BLA; and (iv) accordingly, the Company’s public statements were materially false and misleading at all material times.
You have until the lead applicant’s deadline to ask the court to appoint you as the lead applicant. Your ability to participate in any recovery does not require you to serve as the principal applicant.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut and Washington DC. Lawyer advertising. Past results do not guarantee similar results.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Edouard Korsinsky, Esq.
55 Broadway, 10th floor
New York, New York 10006
Phone. : (212) 363-7500
Fax: (212) 363-7171
THE SOURCE: Levi & Korsinsky, LLP
See the source version on accesswire.com: